Key Takeaways:
Fractyl Health faces a securities class action after GUTS shares fell 74.86% on Revita data concerns.
"Investors deserve transparency about material risks before a company taps the public markets for capital," Joseph E. Levi, founding partner at Levi & Korsinsky, said. "The complaint here alleges that Fractyl Health raised roughly $76.7 million in back-to-back offerings on days that coincided with favorable interim Revita readouts, while operational problems at a study site allegedly went undisclosed."
The lawsuit, filed by Bronstein, Gewirtz & Grossman LLC, covers investors who purchased Fractyl securities between January 13, 2025 and January 29, 2026. GUTS fell $1.245 per share, or 68.03%, to close at $0.585 on January 29, 2026, after the company released six-month REMAIN-1 Midpoint Cohort data showing Revita-treated patients experienced 4.5% weight regain versus 7.5% in the sham arm. The stock fell another $0.125, or 21.37%, to close at $0.46 on January 30 after Morgan Stanley downgraded the stock to Equal-weight from Overweight and cut its price target to $2.00 from $8.00.
The complaint alleges Fractyl raised approximately $76.7 million in net proceeds from two offerings in August and September 2025 while shares traded at prices inflated by favorable interim Revita data. The court has set October 20, 2026 as the deadline to apply for lead plaintiff appointment.
The complaint alleges Fractyl overstated Revita's efficacy and the reliability of the REMAIN-1 Midpoint Cohort results. On September 26, 2025, the company announced that Revita-treated patients "lost an additional 2.5% total body weight" after stopping GLP-1 drugs versus a 10% regain in sham-treated patients. The company sold 60 million shares at $1.00 per share in the September offering.
During a January 29, 2026 investor call, CEO Harith Rajagopalan said central statistical monitoring identified one of six study sites with a high degree of variability in weight regain. Canaccord Genuity later reported that the outlier site had a less comprehensive diet and lifestyle counseling program. Morgan Stanley lowered its probability of success for Revita to 35% from 50%.
The complaint names Fractyl Health, CEO Harith Rajagopalan, and CFO Lisa A. Davidson as defendants, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The plaintiffs allege the company should have disclosed the site issues under Item 105 and that the degrading efficacy results constituted known trends requiring disclosure under Item 303.
The lead plaintiff deadline is October 20, 2026. Investors who purchased GUTS securities during the class period and suffered losses may be eligible to participate. The case highlights the scrutiny clinical-stage companies face when capital raises coincide with interim data releases. For Fractyl, the litigation adds another layer of uncertainty to a stock already trading near $0.46, and investors will watch for further developments as the court considers lead plaintiff appointment.
This article is for informational purposes only and does not constitute investment advice.
